Venus Medtech (Hangzhou) Inc. announced that its CEP device, TriGUARD3, has completed its first clinical application in the PRC on January 15, 2021, which is also its first clinical application in Asia. The board of directors of the Company believes that this is an important milestone for achieving the product layout of "Cerebral embolic protection ­ Balloon ­ Valve". TriGUARD3 is a CEP device designed to provide coverage of all three major aortic vessels (brachiocephalic artery, left carotid artery, and left subclavian artery) to minimize the risk of cerebral damage during TAVR and other structural heart procedures. In addition, VenusA-Plus Transcatheter Prosthetic Aortic Valve Replacement System ­ Retrievable Delivery System ("VenusA-Plus"), a core product independently developed by the Company, has been approved by the Food and Drug Administration of the Ministry of Public Health of Thailand on December 18, 2020, marking a rapid approval of VenusA-Plus in Thailand following its approval in the PRC in November 2020.